Skip to content

BIO: Build Back Better Act weakens U.S. innovation ecosystem, hurts patients

BIO: Build Back Better Act weakens U.S. innovation ecosystem, hurts patients Michelle McMurry-Heath, M.D., Ph.D., president and CEO of the Biotechnology Innovation Organization, released the following statement after the House of Representatives passed the Build Back Better Act on Nov. 19: “The legislation that passed the House today will upend a successful Medicare system and…

Read More

BIO: What happened with the Orphan Drug Tax Credit

BIO: What happened with the Orphan Drug Tax Credit During a busy week in Congress, Democrats included a change to the Orphan Drug Tax Credit that would negatively impact research on rare diseases affecting millions of Americans. The U.S. House of Representatives has several committees marking up the Senate’s $3.5 trillion budget reconciliation package. (Here’s…

Read More

BIO’s fall Congressional preview

The summer calm is grinding to a halt as members of Congress have returned to D.C. for what is sure to be a busy legislative sprint that could potentially impact all sectors of the biotech industry.

Read More

BIO: Where things stand with TRIPS waiver

BIO: Where things stand with TRIPS waiver It’s been a while since we’ve talked about what’s going on at the WTO. Here’s the latest news—and why the proposed waiver of vaccine IP is still a bad idea. The status: The World Trade Organization is still considering a proposal backed by India and South Africa (and…

Read More